ATOS Atossa Therapeutics

Atossa to Present at the Sidoti Small-Cap Investor Conference

Atossa to Present at the Sidoti Small-Cap Investor Conference

SEATTLE, June 05, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that the Company will present at the Sidoti Small-Cap Investor Conference being held June 12-13, 2024. The presentation by Steven Quay, M.D., Ph.D., Atossa’s President and Chief Executive Officer, will take place on Thursday, June 13 at 9:15 am eastern time. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.

To register and view a live webcast of the presentation, please visit the event's website at:

Following the conference, a recording of the webcast will be made available on the investor relations page of Atossa’s website:

About Atossa Therapeutics

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. For more information, please visit .

Contact:

Eric Van Zanten

VP, Investor and Public Relations

610-529-6219



EN
05/06/2024

Underlying

ATOSAtossa Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Atossa Therapeutics

 PRESS RELEASE
Free
ATOS Atossa Therapeu...

Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer

Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer SEATTLE, July 02, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced the appointment of Heather Rees as the Company’s new Chief Financial Officer (CFO). Ms. Rees most recently served as Atossa’s Senior Vice President of Finance and Principal Accounting Officer. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. Ms. Rees brings almost 30-years ...

14h / 21m 1 EN
 PRESS RELEASE
Free
ATOS Atossa Therapeu...

Atossa Therapeutics Announces Updated Protocol for Clinical Trial Eval...

Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer SEATTLE, June 28, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced protocol changes in the previously initiated study to evaluate Atossa’s proprietary (Z)-endoxifen in combination with abemaciclib (VERZENIO®), a cyclin-dependent kinase (CDK) 4/6 inhibitor marketed by Eli Lilly and Company. The study is investigating the combination as a neoadjuvant treatment ...

June 28, 2024 1 EN
 PRESS RELEASE
Free
ATOS Atossa Therapeu...

Atossa Set to Join Russell 3000® Index Effective June 28, 2024

Atossa Set to Join Russell 3000® Index Effective June 28, 2024 SEATTLE, June 17, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced its expected upcoming inclusion in the Russell 3000® Index, according to preliminary Russell reconstruction information posted on the FTSE Russell website. The newly reconstructed index will take effect after the market closes on June 28, 2024. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on br...

June 17, 2024 1 EN
 PRESS RELEASE
Free
ATOS Atossa Therapeu...

Atossa to Present at the Sidoti Small-Cap Investor Conference

Atossa to Present at the Sidoti Small-Cap Investor Conference SEATTLE, June 05, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that the Company will present at the Sidoti Small-Cap Investor Conference being held June 12-13, 2024. The presentation by Steven Quay, M.D., Ph.D., Atossa’s President and Chief Executive Officer, will take place on Thursday, June 13 at 9:15 am eastern time. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with ...

June 5, 2024 1 EN
 PRESS RELEASE
Free
ATOS Atossa Therapeu...

Atossa Therapeutics Announces Support of Clinical Study Testing New, A...

Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model SEATTLE, May 28, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced support for a new Phase 2 study designed to validate an innovative, artificial intelligence driven, breast cancer risk assessment model. The SMART (Stockholm MAmmography Risk stratified Trial) study will test an individualized, imaging-based screening model designed to identify women with the highest risk of developing breast cancer in...

May 28, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch